Dr. Tabrizian on the Rationale for Examining Cemiplimab in HCC

Media coverage

• Title	Dr. Tabrizian on the Rationale for Examining Cemiplimab in HCC
  Media name/outlet	OncLive
  Country/Territory	United States
  Date	22/04/21
  URL	https://www.onclive.com/view/dr-tabrizian-on-the-rationale-for-examining-cemiplimab-in-hcc
  Persons	Parissa Tabrizian